Publications by authors named "P Haber"
Background & Aims: The combination of atezolizumab and bevacizumab (atezo+bev) is the current standard of care for advanced hepatocellular carcinoma (HCC), providing a median overall survival (OS) of 19.2 months. Here, we aim to uncover the underlying cellular processes driving clinical benefit versus resistance to atezo+bev.
View Article and Find Full Text PDFAims: This study tested the efficacy and safety of a 12-week course of lisdexamfetamine in reducing methamphetamine use, an outcome which is associated with improvements in health and wellbeing, in people dependent on methamphetamine.
Design, Setting And Participants: This study was a randomised double-blind placebo-controlled trial conducted in six specialist outpatient clinics in Adelaide, Melbourne, Newcastle and Sydney, Australia (2018-2021). Participants were164 adults with methamphetamine dependence, reporting at least 14 use days out of the previous 28 days (62% male, 38% female, < 1% other; mean age 39 years).
The term cholangiocarcinoma (CCA) includes a group of malignant tumors that develop in the efferent bile ducts and are characterized by a high degree of heterogeneity. These differences between intrahepatic, perihilar and distal CCAs run through all aspects of the disease including the etiology, pathogenesis, symptoms, diagnostics and treatment. This review article presents the current developments in this field of diseases.
View Article and Find Full Text PDFArticle Synopsis
- The study examines factors influencing the completion of alcohol and other drug (AOD) treatment, focusing on both demographic and service-level aspects among a large cohort in New South Wales, Australia.
- It found that around 69.8% of participants completed treatment at least once, with differences in completion rates based on the type of substance, treatment modality, and referral source.
- Specifically, amphetamine treatments had the lowest completion rates, while mandated treatments through criminal justice agencies and certain AOD modalities, like involuntary treatments, showed significantly higher completion rates.